JNJ-55308942

DRUG2 trials

Sponsors

Janssen-Cilag International NV, Janssen Pharmaceutica N.V., Belgium

Conditions

Bipolar DisorderHealthy

Phase 1

A Positron Emission Tomography (PET) Study to Investigate P2X7 Receptor Occupancy by JNJ-55308942 Using [18F]-JNJ-64413739

CompletedNCT03437590

Janssen-Cilag International NVHealthy

Start: 2018-03-15End: 2018-10-19Updated: 2025-04-27

Phase 2

A Study of JNJ-55308942 in the Treatment of Bipolar Depression

CompletedNCT05328297

Janssen Pharmaceutica N.V., BelgiumBipolar Disorder

Start: 2022-06-03End: 2024-05-17Updated: 2025-07-11